March of the Biosimilars

This Event has Passed

Where

Virtual

When

{{getUserDateTimezone("1710435600").singleDate}}
{{getUserDateTimezone("1710435600").time}} - {{getUserDateTimezone("1710439200").time}} {{getClientTimezoneName()}}

About

Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drug makers are marketing these medicines? Join leading experts to discuss the impact on the industry and patients.

Sponsor Introduction

Thomas Newcomer, vice president and head of U.S. Market Access, Samsung Bioepis (sponsor)

Featured Speakers

Chris M. Brown, president, McAteer
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
Fran Gregory, MBA, PharmD, vice president of emerging therapies, Cardinal Health
Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)